title: Discordant heart xenografts in the rat. Additional effect of plasma exchange and cyclosporine, cyclophosphamide, or splenectomy in delaying hyperacute rejection.
abstract: Natural antidonor antibodies are known to play a prominent role in hyperacute xenograft rejection. The aim of this work was to devise an experimental protocol to prolong the survival time of guinea pig heart xenografts transplanted into rats. A technique of continuous plasma exchange adapted to small animals was used to remove the natural cytotoxic antibodies from the recipient prior to the transplantation. In some experiments, cyclosporine (CsA), cyclophosphamide (CY), or splenectomy were associated with the plasma exchange. In this highly discordant xenogenic donor-recipient combination, the mean graft survival time in nontreated rats was 16 min. When an exchange of 1.5 plasma volume was performed 24 hr before the transplantation, no prolongation of the graft survival time was observed. When CsA, CY, or splenectomy were associated with the plasma exchange, the graft survival time was significantly increased by more than 2500% (up to 418 min with CsA). When used isolately, none of these 3 immunosuppressive methods was able to prolong the graft survival time. Natural cytotoxic antibodies were monitored by a complement-mediated cytotoxicity assay. After a plasma exchange, the titers decreased from 1:16-1:32 to 1:1-1:2. When no immunosuppressive method was associated with the plasma exchange, the antibodies returned to their initial level within the 24 hr that preceded the transplantation, and the graft was rejected as in nontreated animals. When an immunosuppressive method was associated with the plasma exchange, and particularly in the case of CsA, the titers remained low, and the hyperacute rejection was delayed. Therefore, it can be concluded that plasma exchanges, associated with CsA, are an efficient experimental protocol in the rat to increase the survival time of guinea pig heart xenografts. The effect of the treatment is correlated with the decrease in natural cytotoxic antidonor antibodies.
authors.affiliation: Clinique Chirurgicale, Hôpital Cochin, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Van de Stadt
authors.forename: B
authors.initials: B
authors.lastname: Vendeville
authors.forename: B
authors.initials: B
authors.lastname: Weill
authors.forename: S
authors.initials: S
authors.lastname: Crougneau
authors.forename: A
authors.initials: A
authors.lastname: Michel
authors.forename: F
authors.initials: F
authors.lastname: Filipponi
authors.forename: P
authors.initials: P
authors.lastname: Icard
authors.forename: M
authors.initials: M
authors.lastname: Renoux
authors.forename: A
authors.initials: A
authors.lastname: Louvel
authors.forename: D
authors.initials: D
authors.lastname: Houssin
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology; D003524:Cyclosporins / Q000494:pharmacology*; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006168:Guinea Pigs; D016027:Heart Transplantation; D008297:Male; D010951:Plasma Exchange; D051381:Rats; D011917:Rats, Inbred Lew; D013156:Splenectomy; D014183:Transplantation, Heterologous
chemical_list: D003524:Cyclosporins; D003520:Cyclophosphamide